DEA Plays Chemical Whack-A-Mole With Designer Drug CUMYL-PEGACLONE
Published Date: 12/11/2025
Proposed Rule
Summary
The Drug Enforcement Administration wants to make the temporary ban on CUMYL-PEGACLONE permanent by placing it in Schedule I, meaning it’s considered very risky and illegal to handle without special permission. This affects anyone who makes, sells, studies, or possesses this substance. Comments and hearing requests are open until January 12, 2026, so speak up before then!
Analyzed Economic Effects
3 provisions identified: 0 benefits, 3 costs, 0 mixed.
Unauthorized handling may bring penalties
The proposal says any activity with CUMYL-PEGACLONE that is not authorized under the Controlled Substances Act would be unlawful and may subject the person to administrative, civil, and/or criminal sanctions under Schedule I rules.
CUMYL-PEGACLONE moved to Schedule I
The Drug Enforcement Administration proposes to permanently place CUMYL-PEGACLONE (also called SGT-151) in Schedule I, making permanent the temporary controls first ordered on December 12, 2023. If finalized, anyone who manufactures, distributes, imports, exports, researches, or possesses this substance would be subject to the regulatory controls for Schedule I substances; comments are due January 12, 2026.
Required registrations, security, and controls
If finalized, anyone handling CUMYL-PEGACLONE must follow Schedule I requirements: register with DEA, meet Schedule I security rules, use specified labeling and packaging, comply with manufacturing quotas, keep initial and biennial inventories, maintain records and reports, use required order forms, and follow import/export controls.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-11526, Implementation of the Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment for Patients and Communities Act of 2018: Dispensing and Administering Controlled Substances for Medication-Assisted Treatment
Starting July 9, 2026, new rules make it easier for doctors and pharmacies to provide medicine that helps people recover from opioid addiction. These changes affect healthcare providers by expanding who can give medication-assisted treatment and how pharmacies can deliver these medicines. The goal? Faster, safer access to treatment with clear rules that save time and support recovery.
2026-10128, Revision of Applications for Manufacturing and Procurement Quotas
The DEA wants to update how companies apply for permission to make and buy certain controlled drugs and chemicals. These changes will make the rules clearer, help prevent drug shortages, and ensure enough supply for medical and scientific needs. If you’re a manufacturer or involved in this process, get ready to follow new steps and share your thoughts by July 20, 2026.
2025-05007, Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients
Starting December 31, 2025, veterans can get buprenorphine treatment and follow-up care through telemedicine, making it easier to access help for opioid use disorder without leaving home. This change affects veterans using VA health services and aims to improve treatment access while the government reviews feedback and policies. No new costs are mentioned, but the delay gives agencies time to ensure the rules work well.
2025-02793, Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients
The government is giving veterans easier access to buprenorphine treatment through telemedicine, letting them get care remotely. This change affects veterans using VA health services and aims to make treatment smoother and more convenient. The new rules were supposed to start February 18, 2025, but now they’ll kick in on March 21, 2025, while the government gathers public feedback.
2026-22843, Proposed Aggregate Production Quotas for Schedule I and II Controlled Substances and Assessment of Annual Needs for the List I Chemicals Ephedrine, Pseudoephedrine, and Phenylpropanolamine for 2027
The DEA is setting limits on how much of certain controlled drugs and chemicals can be made in 2027. This affects drug makers and anyone involved in producing or handling these substances. They’re asking for public comments by December 10, 2026, before finalizing the amounts, which helps keep drug supply safe and balanced.
2026-22842, Adjustment to the 2026 Aggregate Production Quota for d,l-Amphetamine, d-Amphetamine (for Sale), Hydromorphone and Methylphenidate (for Sale) Pursuant to 21 U.S.C. 826(h)
The DEA is boosting the 2026 production limits for four important medicines: d,l-amphetamine, d-amphetamine (for sale), hydromorphone, and methylphenidate (for sale). This change helps fix shortages and keeps medicines flowing smoothly. The new quotas take effect right away on November 10, 2026, so manufacturers can ramp up production without delay.
Previous / Next Documents
Previous: 2025-22490, Guidance on Response Programs for Unauthorized Access to Member Information and Member Notice
The National Credit Union Administration (NCUA) is updating how it shares rules about handling unauthorized access to member info. Instead of keeping detailed guidance in the official rulebook, they’ll publish it separately to make updates easier and reduce confusion for credit unions. This change affects federally insured credit unions and invites public comments until February 9, 2026, with no new costs involved.
Next: 2025-22499, Establishment of Class E Airspace; Providence Seaside Hospital Heliport, Seaside, OR
The FAA is planning to create new Class E airspace around Providence Seaside Hospital Heliport in Seaside, Oregon, starting 700 feet above the ground. This change helps pilots safely use GPS-based flight paths for takeoffs and landings, making helicopter flights smoother and safer. If you want to share your thoughts, make sure to comment by January 26, 2026—no costs or fees involved!